Ceftriaxone has been in shortage since 2023. Learn why this critical antibiotic is so hard to find in 2026, what's causing supply issues, and what you can do.
You went to the hospital, urgent care, or your doctor's office — and they told you they couldn't get Ceftriaxone. Maybe your treatment was delayed. Maybe you were switched to a different antibiotic without much explanation. If this has happened to you, you're far from the only one.
Ceftriaxone (formerly sold under the brand name Rocephin) has been in an active drug shortage since 2023, and as of early 2026, supply problems continue to affect hospitals, clinics, and patients across the United States. In this post, we'll break down what Ceftriaxone is, why it's so hard to find, and what you can do about it.
Ceftriaxone is a third-generation cephalosporin antibiotic that's given by injection — either into a vein (IV) or into a muscle (IM). It's one of the most commonly used injectable antibiotics in the world, prescribed for a wide range of serious bacterial infections including:
Ceftriaxone is valued because it works against a broad range of bacteria, it's effective in a single daily dose, and it has a relatively good safety profile. It's a workhorse antibiotic in emergency rooms and hospitals nationwide.
To learn more about how this medication works in your body, check out our guide on how Ceftriaxone works.
The Ceftriaxone shortage isn't caused by a single problem — it's the result of several overlapping issues that have been building for years. Here are the main reasons:
Ceftriaxone is a sterile injectable medication, which means it has to be manufactured in specialized facilities under strict quality controls. Several major manufacturers, including Hikma Pharmaceuticals, have reported production delays due to equipment maintenance, quality control issues, and capacity constraints. When one manufacturer falls behind, the entire supply chain feels the impact.
Lupin Pharmaceuticals has discontinued its Ceftriaxone products entirely, reducing the number of suppliers in the market. The original brand-name product, Rocephin (made by Roche), was discontinued years ago. With fewer companies making Ceftriaxone, any disruption at a remaining manufacturer creates a bigger gap in supply.
The sterile injectable drug market in the U.S. is dominated by a small number of manufacturers. This concentration means the entire supply of critical medications like Ceftriaxone depends on just a handful of production lines. Industry-wide, sterile injectable drugs account for a disproportionate share of all drug shortages.
Ceftriaxone demand has remained high due to its effectiveness and the limited number of convenient alternatives. It's a go-to antibiotic for emergency departments, and when other antibiotics face their own shortages (like Cefazolin), providers often turn to Ceftriaxone as a substitute — which further strains supply.
For a deeper look at the current shortage situation, read our Ceftriaxone shortage update for 2026.
Being told that a medication you need isn't available is stressful, but there are steps you can take:
Instead of calling pharmacies and hospitals one by one, use Medfinder to search for Ceftriaxone availability near you. Medfinder checks stock across a network of pharmacies and clinics so you can find where the medication is in stock right now.
If Ceftriaxone isn't available, your doctor can consider alternatives depending on your specific infection. Options may include Cefotaxime (a similar third-generation cephalosporin), Cefepime (a fourth-generation cephalosporin), or Ertapenem for certain resistant infections. Learn more in our post on alternatives to Ceftriaxone.
Large chain pharmacies often experience shortages first because they serve high volumes. Independent pharmacies and specialty compounding pharmacies may have access to different supply channels. It's worth making a few calls.
If you need Ceftriaxone for an outpatient infusion (like for Lyme disease treatment), ask your prescribing doctor to check with the hospital pharmacy. Hospital pharmacies sometimes have stock that isn't reflected in retail pharmacy inventories.
Home infusion companies specialize in delivering IV medications and may have supply chains that differ from typical retail or hospital pharmacies. Your insurance may cover home infusion therapy, and these companies often have better access to injectable antibiotics during shortages.
The Ceftriaxone shortage is a real and ongoing problem that has affected patients across the country since 2023. Manufacturing delays, supplier consolidation, and high demand are the main drivers. While the situation is frustrating, there are tools and strategies that can help you get the treatment you need.
If you're struggling to find Ceftriaxone, start with Medfinder to check which pharmacies and clinics near you have it in stock. And don't hesitate to talk to your doctor about alternative antibiotics if the shortage is delaying your treatment.
For tips on tracking down this medication, check out our guide on how to find Ceftriaxone in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
